Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L, et al
At the time, $13bn was an unbelievable number, and led many to question whether the blockbuster era would soon be over (Ive a longer case study on Lipitor here And, Id always recommend my interview with John LaMattina, the genius behind Lipitor) Other Examples : Abilify (the sixth atypical antipsychotic) succeeded via broad indications Cimzia (a late TNF inhibitor) hit $2B peak via differentiation Eliquis (anticoagulant) won via a better safety profile The McKonsultancies might well advise leaders to protect leads - seeing sales erode to a competitor does tend to make companies more conservative - but we would recommend that companies maintain a pioneer spirit
Trigger Inflammatory Responses: This can prove detrimental, especially to the efficacy of the donated plasma
Third-party certification isn't currently disclosed
In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat